GTC antithrombin ATryn assigned priority review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA assigns priority review to GTC Biotherapeutics' antithrombin ATryn, firm says Sept. 4. The BLA's target user fee date is Feb. 7, 2009. GTC filed the final portion of the rolling BLA for ATryn Aug. 7 for prophylactic treatment of deep vein thrombosis and other thromboembolisms in patients with hereditary antithrombin deficiency who are undergoing high risk surgical and childbirth procedures. Ovation Pharmaceuticals has the license for development and marketing of ATryn in the U.S. The drug is already approved for antithrombin hereditary deficiency in Europe, where a Phase II trial is underway testing ATryn in disseminated intravascular coagulation associated with severe sepsis. Top-line results are due in the second half of next year
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.